Urothelial carcinoma - historical
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main bladder cancer page for current regimens.
9 regimens on this page
10 variants on this page
|
Metastatic disease, subsequent lines of therapy
Durvalumab monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Efficacy |
---|---|---|---|
Massard et al. 2016 (Study 1108) | 2014-2015 | Phase I/II (RT) | ORR: 31% (95% CI 18 to 47) |
Note: this regimen was intended for patients "who had progressed on, been ineligible for, or refused any number of prior therapies".
Immunotherapy
- Durvalumab (Imfinzi) 10 mg/kg IV over 60 minutes once on day 1
14-day cycle for up to 26 cycles (1 year). Patients could receive another 12 months of treatment if they experienced disease progression, had not received other anticancer treatment, and did not meet criteria for discontinuation.
References
- Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6. link to original article contains protocol link to PMC article PubMed NCT01693562